Alphamab Wins CDE Acceptance for Phase II Trial of Novel Cervical Cancer Therapy JSKN033

Alphamab Oncology ( (HK:9966) ) has provided an announcement.

Alphamab Oncology announced that China’s Center for Drug Evaluation has officially accepted its Investigational New Drug application for a phase II clinical trial of JSKN033, a high-concentration subcutaneous co-formulation of a HER2 bispecific ADC and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The open-label, multicenter study will assess the safety, efficacy and pharmacokinetic/pharmacodynamic profile of JSKN033 plus cisplatin or carboplatin, and potentially bevacizumab, marking a significant step in advancing Alphamab’s novel combination biologic and reinforcing its strategy to build a differentiated oncology portfolio that could enhance its competitive position in the global cancer therapeutics market.

The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a leading Chinese biopharmaceutical company specializing in oncology, with a fully integrated proprietary technology platform spanning antibody-drug conjugates (ADCs), bispecific antibodies and multi-functional protein engineering. Its in-house pipeline includes ADCs, monoclonal and bispecific antibodies at various stages of development, with one product already approved by China’s National Medical Products Administration and multiple candidates in phase III or pivotal clinical trials, positioning the company as an innovator in advanced antibody-based cancer therapies.

Average Trading Volume: 2,670,520

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.15B

See more insights into 9966 stock on TipRanks’ Stock Analysis page.